CN105246875A - 茚满衍生物及其制备方法和在医药上的应用 - Google Patents

茚满衍生物及其制备方法和在医药上的应用 Download PDF

Info

Publication number
CN105246875A
CN105246875A CN201480029372.5A CN201480029372A CN105246875A CN 105246875 A CN105246875 A CN 105246875A CN 201480029372 A CN201480029372 A CN 201480029372A CN 105246875 A CN105246875 A CN 105246875A
Authority
CN
China
Prior art keywords
salt
alkyl
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480029372.5A
Other languages
English (en)
Inventor
张晨
何平
魏用刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Priority to CN201480029372.5A priority Critical patent/CN105246875A/zh
Publication of CN105246875A publication Critical patent/CN105246875A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及一种茚满衍生物及其制备方法和在医药上的应用，具体而言本发明涉及通式(I)所示的化合物或者其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐、共晶或者前药、它们的制备方法、包括其药物组合物以及本发明的化合物药物组合物在医药上的应用，特别作为GPR40受体(G蛋白偶联受体)激动剂的应用，

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201480029372.5A 2013-09-03 2014-09-03 茚满衍生物及其制备方法和在医药上的应用 Pending CN105246875A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480029372.5A CN105246875A (zh) 2013-09-03 2014-09-03 茚满衍生物及其制备方法和在医药上的应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2013103949381 2013-09-03
CN201310394938 2013-09-03
PCT/CN2014/085848 WO2015032328A1 (zh) 2013-09-03 2014-09-03 茚满衍生物及其制备方法和在医药上的应用
CN201480029372.5A CN105246875A (zh) 2013-09-03 2014-09-03 茚满衍生物及其制备方法和在医药上的应用

Publications (1)

Publication Number Publication Date
CN105246875A true CN105246875A (zh) 2016-01-13

Family

ID=52627813

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480029372.5A Pending CN105246875A (zh) 2013-09-03 2014-09-03 茚满衍生物及其制备方法和在医药上的应用

Country Status (2)

Country Link
CN (1) CN105246875A (zh)
WO (1) WO2015032328A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109134409B (zh) * 2017-06-14 2023-09-29 中国科学院上海药物研究所 盐酸美呋哌瑞多晶型物及其制备方法与应用
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1726580A1 (en) * 2004-03-15 2006-11-29 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
WO2007106469A2 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2008001931A2 (en) * 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
CN102421739A (zh) * 2009-04-22 2012-04-18 安斯泰来制药株式会社 羧酸化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013689A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
RU2008118156A (ru) * 2005-10-07 2009-11-20 Астеллас Фарма Инк. (Jp) Производное триарилкарбоновой кислоты

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1726580A1 (en) * 2004-03-15 2006-11-29 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
WO2007106469A2 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2008001931A2 (en) * 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
CN102421739A (zh) * 2009-04-22 2012-04-18 安斯泰来制药株式会社 羧酸化合物

Also Published As

Publication number Publication date
WO2015032328A1 (zh) 2015-03-12

Similar Documents

Publication Publication Date Title
CN105246875A (zh) 茚满衍生物及其制备方法和在医药上的应用
CN105143181B (zh) 三元并环羧酸类衍生物、其制备方法及其在医药上的应用
JP6923683B2 (ja) オピオイド受容体リガンド並びにそれらの使用方法及び製造方法
CN104093716B (zh) 联芳醚磺酰胺化合物及其作为治疗剂的用途
CN104507921B (zh) 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
WO2021197464A1 (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN105683157B (zh) 用作钠通道调节剂的磺酰胺类
CN104870429B (zh) 苯并呋喃衍生物、其制备方法及其在医药上的应用
TW202115038A (zh) 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
JP5046643B2 (ja) 血管新生阻害剤としての６員環アミノ−アミド誘導体
WO2021254470A1 (zh) 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN115175679A (zh) 治疗雌激素受体相关疾病的方法
CN104364235B (zh) 作为ttx‑s阻断剂的酰胺衍生物
US20100184860A1 (en) Novel Carboxylic Acid and Antidepressant Composition Containing the Same as Active Ingredient
JP2022506802A (ja) 大環状チロシンキナーゼ阻害剤及びその用途
CN114149423A (zh) 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN104507898B (zh) 苯酚衍生物及其制备方法和在医药上的应用
CN104812755A (zh) 作为ttx-s阻断剂的吡唑并吡啶衍生物
CN103360342B (zh) 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
CN115477634B (zh) 用于镇痛的化合物及其医药用途
CN111635373A (zh) 多环磺酰胺类RORγ调节剂
WO2023143388A1 (zh) 作为钾通道调节剂的酰胺类化合物及其制备和应用
CN108623555B (zh) 一种苯并氧杂䓬类化合物、及其制备方法和药物组合物与用途
CN107522641B (zh) 联芳基脲类衍生物或其盐及其制备方法和用途
CN105492430A (zh) 取代的苯并噁唑及其使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160113